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Purpose   Skeletal metastases are common in patients with pros-
tate cancer, and they can be a source of considerable morbidity. 
We analyzed patient survival after surgery for skeletal metastases 
and identified risk factors for reoperation and complications.
Patients and methods   This study included 306 patients with 
prostate cancer operated for skeletal metastases during 1989–
2010. Kaplan-Meier analysis was used to calculate survival. Cox 
multiple regression analysis was performed to study risk factors, 
and results were expressed as hazard ratios (HRs).
Results   The median age at surgery was 72 (49–94) years. The 
median survival after surgery was 0.5 (0–16) years. The cumula-
tive 1-, 2-, and 3-year survival after surgery was 29% (95% CI: 
24–34), 14% (10–18), and 8% (5–11). Age over 70 years (HR 1.4), 
generalized metastases (HR 2.4), and multiple skeletal metas-
tases (HR 2.3) resulted in an increased risk of death after sur-
gery. Patients with lesions in the humerus (HR 0.6) had a lower 
death rate. The reoperation rate was 9% (n = 31). The reasons for 
reoperation were deep wound infection (n = 10), hematoma (n = 
7), material (implant) failure (n = 3), wound dehiscence (n = 3), 
increasing neurological symptoms (n = 2), prosthetic dislocation 
(n = 2), and others (n = 4). 
Interpretation   This study involves the largest reported cohort 
of patients operated for skeletal lesions from prostate cancer. Our 
survival data and analysis of predictors for survival help to set 
appropriate expectations for the patients, families, and medical 
staff.

Advances in the treatment of prostate cancer have extended 
life expectancy (Berruti et al. 2000, Carlin and Andriole 2000, 
Saad et al. 2006). Approximately 70% of the patients with 
advanced disease can be expected to develop skeletal metasta-
ses (Coleman 2001).
The role of orthopedic surgery in patients with skeletal 
metastases is to treat spinal cord compression and existing or 
impending pathological fractures in an effort to relieve pain 
and restore function. Information on outcomes following 
surgery for skeletal metastases is important for the patients 
involved, for their families, and for treating physicians (Wedin 
et al. 2005, Forsberg et al. 2011).
Skeletal metastases from other malignancies are most often 
osteolytic whereas skeletal metastases from prostate cancer 
are most often osteoblastic, which may mean unique treat-
ment considerations. However, little attention has been paid 
to survival and postoperative complications in patients with 
metastatic prostate lesions. 
We have determined patient survival following surgery for 
symptomatic skeletal metastases in a large cohort of prostate 
cancer patients. A secondary aim was to identify patient-
related and procedure-related risk factors for complications 
and reoperation.
 
Patients and methods
This study involved a consecutive series of patients with 
prostate cancer who were operated for skeletal metastases 
from 1989 through 2010. Only patients who had their pri-
mary operation at our hospital were included in the study. 
All data are based on the Karolinska Skeletal Metastasis 
Register (Wedin and Bauer 2005). This quality-control data-
base prospectively collects individual-based information for 
cancer patients admitted to the Karolinska University Hospi-
tal in Stockholm. The criterion for inclusion is surgical treat-
ment of skeletal metastases. Data on patient identity, age, 
sex, primary tumor, location of metastases, type of metas-
tases (single skeletal, multiple skeletal, or generalized), sur-Acta Orthopaedica 2012; 83 (1): 74–79  75
gical procedures (method of fixation and type of implant), 
and postoperative complications are registered. Generalized 
metastases are defined as skeletal metastases in combination 
with visceral metastases. Pathological fractures were defined 
as skeletal metastases resulting in a dislocation (kyphosis or 
loss of height for vertebral fractures).
Neurological function in patients with spinal metastases 
was assessed by the Frankel classification of motor and sen-
sory compromise. It is standard for the neurological function 
to be assessed preoperatively and within 2 weeks postopera-
tively. Data for the Frankel classification were collected retro-
spectively from medical records. Postoperative radiotherapy 
was offered routinely to all patients. 114 patients in the pres-
ent analysis were included in a previous publication from our 
institution (Jansson and Bauer 2006).
Statistics
Continuous descriptive statistics used median values and 
ranges. Kaplan-Meier analysis was used to construct the 
cumulative survival with 95% confidence intervals (CIs) after 
surgery for skeletal metastases. If patients had more than 1 
surgical procedure, only the first operation was accounted for 
in the survival analysis.
Cox multiple regression was used to study risk factors for (1) 
death, (2) any complication, and (3) reoperation. The results 
were expressed as hazard ratios (HRs) with corresponding 
CIs. If a HR is > 1, the patients at risk are dying at a faster 
rate or have a higher risk of complications than the patients in 
the reference group. The assumption of proportional hazards 
was investigated using graphs of the log-minus-log survivor 
function against log t over grouped values of the covariates. 
No signs of insufficient proportionality were detected in the 
hazard functions, and the log-log plots ran parallel for all 
covariates. Crude risk factors studied in the simple Cox model 
were age, anatomical location of the metastasis, type of metas-
tasis (single skeletal, multiple skeletal, or generalized), and 
pathological fracture. All variables were adjusted for in the 
multiple Cox model. Wilcoxon’s signed ranks test was used to 
compare preoperative and postoperative neurological function 
in patients with spine metastases. The level of significance 
was set at p ≤ 0.05. All statistical analyses were performed 
using the PASW statistics package version 18.
 
Results
We identified 306 patients who met the inclusion criteria; 
these patients underwent 358 surgical procedures. No patients 
were excluded from analysis. 16% of the patients had more 
than 1 site of surgery. The median age at surgery was 72 (49–
94) years. Most subjects (62%) were aged 70 years or older. At 
surgery, most patients had multiple skeletal metastases (73%) 
followed by generalized metastases (20%) (Table 1).
54% of the skeletal lesions were situated in the spine, fol-
lowed by the femur (30%), the humerus (8%), and the pelvis 
(8%) (Table 2). Approximately half of the patients operated in 
Table 1. Baseline characteristics of study 
patients at first surgery
 No.
Patients 306
  1 operation  258 (84%)
  2 operations    44 (15%)
  3 operations      4 (1%)
Median age    72 (49–94)
Age group 
  < 60 years    27 (9%)
  60–69 years    90 (29%)
  > 70 years  189 (62%)
Metastases 
  Single skeletal    20 (7%)
  Multiple skeletal  224 (73%)
  Generalized    62 (20%)
Pathological fractures 
 Spinal 
     Yes    80 (45%)
     No    96 (55%)
   Non-spinal 
       Yes  123 (95%)
       No      7 (5%)
Table 2. Anatomical locations and surgical procedures
 No.
Anatomical locations  358
  Spine  193 (54%)
    Cervical      1
     Thoracic  165
     Lumbar    27
   Femur  106 (30%)
    Femoral neck    37
     Trochanteric    27
     Subtrochanteric    33
     Diaphysis      9
   Humerus    28 (8%)
     Proximal      9
     Diaphysis    17
     Distal      2
   Pelvis    28 (8%)
  Tibia      2 (1%)
  Radius      1 (0%)
Surgical procedures  358
   Spinal 
     Decompression    70 (36%)
     Decompression + bone cement    11 (6%)
     Decompression + stabilization  112 (58%)
   Non-spinal 
     Prosthesis    95 (58%)
    Osteosynthesis    66 (40%)
     Other      4 (2%)
  Bone cement 
    Yes  125 (35%)
     No  233 (65%)
 Curetage 
     Yes    26 (7%)
     No  332 (93%)76  Acta Orthopaedica 2012; 83 (1): 74–79
the spine had a vertebral pathological fracture. The main indi-
cation for spinal operations was motor weakness due to spinal 
cord compression (97%); 5 patients were operated on because 
of painful instability. Regarding surgical procedures for spinal 
metastases, 58% of the cases underwent decompression in 
combination with stabilization (Table 2). The overall neuro-
logical function in patients with vertebral metastases improved 
after surgery (p < 0.001). Most cases (55%) improved at least 
1 Frankel grade, 39% maintained their neurological function, 
and 6% deteriorated (Figure 1). Preoperatively, 75% of the 
patients were non-ambulatory (Frankel A, B, or C) and 25% 
were ambulatory (Frankel D or E). Postoperatively, 38% of the 
spine patients were non-ambulatory and 62% were ambulatory.
Non-spinal surgical procedures were most often implanta-
tion of joint prostheses (58%) followed by internal fixation 
with an internal-fixation device (40%). Most subjects had 
pathological fractures (95%), i.e. prophylactic surgery for 
impending fractures was only performed in 5% of the non-
spinal cases (Table 1).
Survival 
The median survival time for the entire cohort after the first 
surgical procedure was 0.5 (0–16) years. The median survival 
time after surgery for patients with spinal metastases was 0.5 
(0–16) years and for non-spinal metastases it was 0.5 (0–9) 
years. At the end of the study period, 94% of the patients had 
died. The cumulative 1- and 2-year survival after surgery was 
29% (CI: 24–34) and 14% (CI: 10–18) (Figure 2).
Simple Cox regression analysis revealed an increased risk of 
death after surgery for patients with lesions in the femur (HR 
1.3), pathological fractures (HR 1.3), generalized metastases 
(HR 2.1), and multiple skeletal metastases (2.2). The corre-
sponding multiple analysis revealed that older age (HR 1.4), 
generalized metastases (HR 2.4), and multiple skeletal metas-
tases (HR 2.3) were significantly associated with an increased 
risk of death, while patients with lesions in the humerus (HR 
0.7) had a significantly lower death rate (Table 3). We could 
not detect any predictor for reoperations. However, pelvic 
lesions (HR 2.3) were risk factors for any complication in both 
analyses (Table 3). Any complication was defined as either a 
reoperation or a complication that was treated non-surgically.
Figure 1. Pre- and postoperative neurological function in 191 patients 
with spinal metastases, graded according to Frankel (A = complete 
paraplegia, B = no motor function, C = motor function useless, D = 
slight motor deficit, and E = no motor deficit).
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Table 3. Risk of (1) death and (2) any complication after surgery for skeletal metas-
tases in 306 patients with prostate cancer
  Simple Cox regression a  Multiple Cox regression b
Endpoint  HR  (95% CI)  p-value  HR  (95% CI)  p-value
Death (1) 
 Age 
    > 70 years  1.3  (1.0–1.6)  0.07  1.4  (1.1–1.9)  0.01
    < 70 years  Ref.      Ref.   
  Anatomical location 
  Femur  1.3 (1.0–1.7)  0.05  1.2  (0.9–1.6)  0.4
  Humerus  0.7 (0.4–1.1)  0.09  0.6  (0.4–1.0)  0.05
    All other  Ref.      Ref.   
  Type of fracture 
  Pathological  1.3 (1.0–1.7)  0.04  1.3  (1.0–1.8)  0.06
    Impending  Ref.     Ref.   
 Metastases 
  Generalized  2.1 (1.2–3.6)  0.006  2.4  (1.4–4.2)  0.002
    Multiple skeletal  2.2  (1.3–3.6)  0.002  2.3  (1.4–3.8)  0.001
    Single skeletal  Ref.      Ref.   
Any complication (2) 
  Anatomical location 
  Pelvis  2.3 (1.3–4.3)  0.007  2.3  (1.2–4.2)  0.01
    All other  Ref.      Ref.
  
a Crude HR. b Adjusted HR.
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Reoperations and complications 
The reoperation rate was 9% (n = 31). The median time to 
reoperation was 0.5 (0–24) months (Table 4). Complications 
that were treated non-surgically occurred in 15% of the cases. 
The median time from surgery to a non-surgically treated 
complication was 0.2 (0–10) months (Table 5). The overall 
complication rate (for any complication) was 24%. 
Discussion
Decision making regarding management of skeletal metastases 
is influenced by factors such as expected duration of survival, 
overall medical condition, rehabilitation potential, and type 
of operation required. The goal is to relieve pain and improve 
function for the maximum amount of time. Patients with a 
short life expectancy may not benefit from surgery due to rapid 
deterioration of health and difficulties in managing the postop-
erative rehabilitation. Some authors have argued that a postop-
erative lifespan of at least 2 months is required for surgery to 
be beneficial in extremity metastases (Harrington et al. 1976) 
and a postoperative lifespan of 3–6 months for spinal lesions 
(Cybulski et al. 1987, Atanasiu et al. 1993, Tomita et al. 1994). 
However, these time points are highly debated, and the deci-
Figure 2. Cumulative survival (with 95% CI) of 306 prostate cancer 
patients after surgery for skeletal metastases.
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Table 4. Reoperations (n = 31)
Reason for reoperation  No., primary  Median time  Treatment
  metastasis  to reoperation
   (months)
Deep wound infection  5, spine
  3, pelvis
  2, femur  1.3  Wound revision
Hematoma  7, spine  0  Drainage
Material failure  3, femur  2.5  Total joint replacement
Wound dehiscence  3, spine  1  Secondary wound closure
Increasing neurological
symptoms  2, spine  0  Extended laminectomy
Prosthetic dislocation  2, pelvis  0.5  Open reduction
      Extraction of prosthesis
Non-union  1, femur  24  Total joint arthroplasty
Periprosthetic fracture  1, femur  5.6  Osteosynthesis
Poor initial fixation  1, femur  0.5  Osteosynthesis
Technical error  1, spine  0.2  Extended laminectomy
 
 
       
Table 5. Complications treated non-surgically (n = 54)
Type of complication  No., primary  Median time to
  metastasis  complication, months
Superficial wound infection  14, spine
    2, femur
    1, pelvis  0.2
Prosthetic dislocation    8, femur
    7, pelvis
    1, humerus  0.5
Pulmonary embolism    2, spine
    2, femur
    1, pelvis  0.1
Pneumonia    4, spine
    1, femur  0.1
Heart failure    2, spine
    1, femur  0
Myocardial infarction    1, spine
    1, pelvis  0
Wound dehiscence    2, spine  1.6
Perioperative hypoxia
(hemiparesis)    1, femur  0
Radial nerve palsy    1, humerus  0
Stroke    1, spine  0
Deep wound infection    1, femur  0
sion to offer surgery remains patient-specific. 
The main indication for almost all spinal 
cases in our study was motor weakness due 
to spinal cord compression. Hill et al. (1993) 
described 70 patients with spinal cord com-
pression secondary to breast cancer. The most 
frequent symptom was motor weakness (96%) 
followed by pain (94%), sensory disturbance 
(79%), and sphincter disturbance (61%). More 
than half of our patients with spinal involve-
ment improved considerably after surgery, i.e. 
at least 1 Frankel grade, and approximately 
40% maintained their neurological function. 
These results are similar to those from a recent 
randomized study, which demonstrated that 
decompressive surgery in combination with 
radiotherapy in patients with metastatic epi-
dural cord compression was superior to radio-
therapy alone (Patchell et al. 2005). 78  Acta Orthopaedica 2012; 83 (1): 74–79
Several studies have identified prognostic clinical variables 
that may help to identify patients with a limited expected 
lifespan after surgery due to skeletal metastases from various 
cancer types. Pathological fractures, visceral metastases, low 
hemoglobin level, number of skeletal metastases, and lung 
cancer as the primary tumor are examples of independent neg-
ative prognostic factors for postoperative survival (Bauer and 
Wedin 1995, Hansen et al. 2004, Nathan et al. 2005, Leithner 
et al. 2008, Forsberg et al. 2011).
Nørgaard et al. (2010) presented survival data on patients 
with prostate cancer in a large population-based cohort study. 
1-year survival was 87% in patients without skeletal metasta-
sis and 47% in those with skeletal metastasis. The combina-
tion of bone metastasis and skeletal-related events reduced the 
1-year survival rate to 40%. Zaikova et al. (2011) presented 
survival data on 260 patients with spine metastases from pros-
tate cancer, treated either with radiotherapy or surgery. They 
found a 1-year survival rate of approximately 35%, which is 
comparable to our findings.
We identified several predictors of survival. Younger 
patients had longer survival after surgery, which has also been 
described in patients after surgery for skeletal lesions from 
renal cell carcinoma (Utzschneider et al. 2009). Noguchi et 
al. (2003) showed that the extent of metastatic skeletal lesions 
(percentage of positive area on a bone scan) is an indepen-
dent predictor of death from disease in patients with prostate 
cancer. We found that patients with a solitary bone metas-
tasis (as compared to multiple metastases) had better sur-
vival, which has been reported previously (Wedin et al. 1999, 
Utzschneider et al. 2009). Skeletal lesions in the humerus 
were also found to be a positive predictor of survival, a find-
ing for which there is no immediate explanation. This could 
represent selection bias; for example, unstable fractures in the 
lower limbs may pose such a significant problem for patients 
and caregivers that surgical stabilization may be appropriate 
even when patients have a limited expectation of survival. 
However, most surgeons at our center do not usually stabilize 
impending pathological humerus fractures in patients with 
short expected survival, and as a result, such patients were 
not included in this study. 
We have confirmed the findings of other authors that patho-
logical fractures negatively influence survival (Oefelein et al. 
2002, Forsberg et al. 2011). However, only 7 of 130 patients 
with non-spinal metastases underwent prophylactic stabiliza-
tion. At our institution, surgery is generally recommended for 
patients with disabling skeletal lesions in addition to those at 
risk of fracture using generally accepted criteria. Although 
efforts have been made to better predict fracture sites and 
avoid an actual fracture (Coleman 2006), it is unclear whether 
prophylactic surgery itself confers a survival benefit. Prophy-
lactic surgery was performed in only 5% of our cases. Most 
patients sustained pathological fractures, which tend to occur 
later in the disease process in a similar fashion to other onco-
logical diagnoses. 
It is often more difficult to treat a pathological fracture than 
a traumatic fracture. Bone-healing is often impaired due to 
extensive bone destruction, a catabolic state, and the effects 
of radiotherapy. The observed reoperation rate of 9% is com-
parable to previously reported surgical failure rates in patho-
logical fractures (Yazawa et al. 1990, Wedin et al. 1999). In 
addition, patients with metastases confined to bone (without 
soft tissue extension) had a lower risk of both reoperation and 
any complication than did those with generalized metastases.
In addition to complications leading to reoperation, one 
must also consider those treated nonoperatively. Periac-
etabular lesions requiring a combination of acetabular metal 
reinforcement ring and hip arthroplasty emerged as an inde-
pendent predictor for a complication. This is largely due to 
the relatively high frequency of hip dislocations, which were 
treated with closed reduction procedures (7 out of 28) in this 
subgroup.
Limitations of our study included the lack of information 
regarding whether adjuvant treatment such as androgen sup-
pression, cytotoxic chemotherapy, or radiation therapy was 
used. However, at our center, adjuvant radiation therapy is 
generally used in all patients with surgically treated metastatic 
bone disease, which is (ideally) started 10–14 days after sur-
gery to allow wound healing.
In conclusion, surgery for vertebral metastases may be the 
best alternative in patients who are expected to live for at least 
another 2–3 months, especially if surgery is likely to result in 
a functional improvement. The patient can, for example, avoid 
being bedridden and perhaps regain/maintain the ability to 
ambulate independently. We believe that stabilization of long 
bone fractures is almost always justified unless the patient has 
reached a terminal stage and death is imminent. 
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